Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov) - Sep 18, 2026 - P2 | N=50 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: Sep 2026 ➔ Dec 2026
Trial initiation date • Basal Cell Carcinoma • Cervical Cancer • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Hodgkin Lymphoma • Kaposi Sarcoma • Lung Cancer • Lymphoma • Merkel Cell Carcinoma • Mucosal Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • Urothelial Cancer • ALK • EGFR • MSI • PD-L1 • ROS1
|